Skip to content

Value of Diaphragmatic Motion Measurement at Ultrasonography to Predict Poor Prognosis in Emergency Department Patients With Acute Respiratory Failure

Pronostic Value of Diaphragmatic Excursion Measurement in Patients With Acute Respiratory Failure in the ED.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04119505
Acronym
PREDIRE
Enrollment
350
Registered
2019-10-08
Start date
2019-11-01
Completion date
2020-12-28
Last updated
2020-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Failure, Dyspnea

Keywords

Diaphragmatic Excursion, Diaphragmatic Dysfunction, Emergency Department, Respiratory insufficiency, Acute respiratory failure

Brief summary

Acute respiratory failure is one of the most common diagnosis in patients admitted in the Emergency Department. Acute respiratory failure is associated with morbidity and mortality. Fifteen percent of patient will require ventilatory support and among them 40% will die. Measurement of diaphragmatic motion (excursion) at ultrasonography is a noninvasive measure, allowing to assess diaphragm dysfunction. It could be useful in predicting poor prognosis in ED patients with respiratory failure . In this study the investigators will compare the prognostic value of diaphragmatic excursion measurement at ultrasonography to that of the National Early Warning Score (NEWS) 2 in patients presenting with acute respiratory failure in the ED The Investigators made the hypothesis that measurement of diaphragmatic excursion in ED patients with acute respiratory failure could be of value in predicting the need for ventilatory support or mortality within 28 days from ED admission

Detailed description

Diaphragmatic dysfunction can be explored by measuring diaphragmatic excursion using ultrasonography in spontaneous ventilation patients. Patients in spontaneous ventilation will undergo both diaphragmatic excursion measurement at ultrasonography and assessment of the News2 score as part of standard care.

Interventions

None listed

Sponsors

Poitiers University Hospital
CollaboratorOTHER
University Hospital, Brest
CollaboratorOTHER
Nord-Vienne Hospital
CollaboratorUNKNOWN
University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age equal or over 18 y.o * Signs of acute respiratory failure defined by RR equal or over 25 br/min and/or signs of increased work of breathing * Patients on spontaneous breathing

Exclusion criteria

* Medical history of diaphragmatic dysfunction including stroke or diaphragmatic paralysis * Patients on ventilatory support at ED admission or prior to inclusion * Patients treated with curare * Trauma patients

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with adverse events28 daysAdverse events are defined as a composite of mortality and/or cardiac arrest and/or need for ventilatory support (including invasive and/or noninvasive ventilation and/or high flow nasal cannula therapy) within 28 days from ED admission.

Secondary

MeasureTime frameDescription
Delay to initiation of ventilatory supportat day 28Ventilatory support is defined as invasive mechanical ventilation or non invasive ventilation or high-flow nasal cannula
Number of patients with adverse events at ED dischargethrough ED stay (up to a day)Adverse events are defined as a composite of mortality and/or cardiac arrest and/or need for ventilatory support (including invasive and/or noninvasive ventilation and/or high flow nasal cannula therapy).
Number of patients with adverse events at hospital dischargethrough hospital stay (up to a week)Adverse events are defined as a composite of mortality and/or cardiac arrest and/or need for ventilatory support (including invasive and/or noninvasive ventilation and/or high flow nasal cannula therapy).

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026